Clinical Trial Update: Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Predicting Treatment Response in Patients With Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating hyperpolarized Carbon-13 pyruvate magnetic resonance spectroscopic imaging to predict treatment response in prostate cancer …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Prostate Adenocarcinoma, PSA Level Greater Than Ten | Phase 2 | Status: WITHDRAWN